三阴性乳腺癌分子靶向治疗研究进展
|
摘要
三阴性乳腺癌(TNBC)是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)表达均为阴性的一类特殊的乳腺癌亚型,具有侵袭性高、易转移、易复发及预后差等临床特点。罹患该病的患者因体内缺乏ER、PR及HER-2的表达,故对内分泌治疗和抗人表皮生长因子2的治疗均不敏感。目前国内外对TNBC还没有标准化的治疗方案,临床上依旧以化疗为主要治疗手段,但化疗的弊处使得寻求新的治疗手段成为当下临床上的迫切需要。近年来越来越多的研究表明分子靶向治疗对三阴性乳腺癌具有相当明显的疗效,本文就近年来TNBC的相关分子靶点研究及治疗进展作一综述。
引文
[1] GERRATANA L,BASILE D,BUONO G,et al. Androgen receptor in triple negative breast cancer:a potential target for the targetless subtype[J]. Cancer Treat Rev,2018,68:102-10.
[2] LEHMANN BD,BAUER JA,CHEN X,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest,2011,121(7):2750-67.
[3] MASUDA H,BAGGERLY KA,WANG Y,et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J]. Clin Cancer Res,2013,19(19):5533-40.
[4] BURSTEIN MD,TSIMELZON A,POAGE GM,et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer[J]. Clin Cancer Res,2015,21(7):1688-98.
[5] JEZEQUEL P,LOUSSOUARN D,GUERIN-CHARBONNEL C,et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours:importance of immune response[J].Breast Cancer Res,2015,17:43.
[6] WANG C,KAR S,LAI X,et al. Triple negative breast cancer in Asia:an insider's view[J]. Cancer Treat Rev,2018,62:29-38.
[7] RICCIARDI GR,ADAMO B,IENI A,et al. Androgen receptor(AR),E-cadherin,and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer(TNBC)patients[J]. PLoS One,2015,10(6):e128368.
[8] GUCALP A,TOLANEY S,ISAKOFF SJ,et al. Phase II trial of bicalutamide in patients with androgen receptor-positive,estrogen receptor-negative metastatic Breast Cancer[J]. Clin Cancer Res,2013,19(19):5505-12.
[9] THAKKAR A,WANG B,PICON-RUIZ M,et al. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer[J]. Breast Cancer Res Treat,2016,157(1):77-90.
[10] RAMPURWALA M,WISINSKI KB,O'REGAN R. Role of the androgen receptor in triple-negative breast cancer[J]. Clin Adv Hematol Oncol,2016,14(3):186-93.
[11] PAPADIMITRIOU M,MOUNTZIOS G,PAPADIMITRIOU CA.The role of PARP inhibition in triple-negative breast cancer:unraveling the wide spectrum of synthetic lethality[J]. Cancer Treat Rev,2018,67:34-44.
[12] HASTAK K,ALLI E,FORD JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose)polymerase inhibition,gemcitabine,and cisplatin[J]. Cancer Res,2010,70(20):7970-80.
[13] AUDEH MW,CARMICHAEL J,PENSON RT,et al. Oral poly(ADP-ribose)polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer:a proof-of-concept trial[J]. Lancet,2010,376(9737):245-51.
[14] LOIBL S,O'SHAUGHNESSY J,UNTCH M,et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer(BrighTNess):a randomised,phase 3 trial[J]. Lancet Oncol,2018,19(4):497-509.
[15] BASELGA J,GOMEZ P,GREIL R,et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer[J]. J Clin Oncol,2013,31(20):2586-92.
[16] TOMAO F,PAPA A,ZACCARELLI E,et al. Triple-negative breast cancer:new perspectives for targeted therapies[J]. Onco Targets Ther,2015,8:177-93.
[17] SU JC,MAR AC,WU SH,et al. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis[J]. Sci Rep,2016,6:28888.
[18] BRUFSKY A,VALERO V,TIANGCO B,et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer:subgroup analysis of the RIBBON-2 trial[J].Breast Cancer Res Treat,2012,133(3):1067-75.
[19] MASSIHNIA D,PEREZ A,BAZAN V,et al. A headlight on liquid biopsies:a challenging tool for breast cancer management[J]. Tumour Biol,2016,37(4):4263-73.
[20] WANG T,SEAH S,LOH X,et al. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway[J]. Oncotarget,2016,7(3):2532-44.
[2] LEHMANN BD,BAUER JA,CHEN X,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest,2011,121(7):2750-67.
[3] MASUDA H,BAGGERLY KA,WANG Y,et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J]. Clin Cancer Res,2013,19(19):5533-40.
[4] BURSTEIN MD,TSIMELZON A,POAGE GM,et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer[J]. Clin Cancer Res,2015,21(7):1688-98.
[5] JEZEQUEL P,LOUSSOUARN D,GUERIN-CHARBONNEL C,et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours:importance of immune response[J].Breast Cancer Res,2015,17:43.
[6] WANG C,KAR S,LAI X,et al. Triple negative breast cancer in Asia:an insider's view[J]. Cancer Treat Rev,2018,62:29-38.
[7] RICCIARDI GR,ADAMO B,IENI A,et al. Androgen receptor(AR),E-cadherin,and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer(TNBC)patients[J]. PLoS One,2015,10(6):e128368.
[8] GUCALP A,TOLANEY S,ISAKOFF SJ,et al. Phase II trial of bicalutamide in patients with androgen receptor-positive,estrogen receptor-negative metastatic Breast Cancer[J]. Clin Cancer Res,2013,19(19):5505-12.
[9] THAKKAR A,WANG B,PICON-RUIZ M,et al. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer[J]. Breast Cancer Res Treat,2016,157(1):77-90.
[10] RAMPURWALA M,WISINSKI KB,O'REGAN R. Role of the androgen receptor in triple-negative breast cancer[J]. Clin Adv Hematol Oncol,2016,14(3):186-93.
[11] PAPADIMITRIOU M,MOUNTZIOS G,PAPADIMITRIOU CA.The role of PARP inhibition in triple-negative breast cancer:unraveling the wide spectrum of synthetic lethality[J]. Cancer Treat Rev,2018,67:34-44.
[12] HASTAK K,ALLI E,FORD JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose)polymerase inhibition,gemcitabine,and cisplatin[J]. Cancer Res,2010,70(20):7970-80.
[13] AUDEH MW,CARMICHAEL J,PENSON RT,et al. Oral poly(ADP-ribose)polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer:a proof-of-concept trial[J]. Lancet,2010,376(9737):245-51.
[14] LOIBL S,O'SHAUGHNESSY J,UNTCH M,et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer(BrighTNess):a randomised,phase 3 trial[J]. Lancet Oncol,2018,19(4):497-509.
[15] BASELGA J,GOMEZ P,GREIL R,et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer[J]. J Clin Oncol,2013,31(20):2586-92.
[16] TOMAO F,PAPA A,ZACCARELLI E,et al. Triple-negative breast cancer:new perspectives for targeted therapies[J]. Onco Targets Ther,2015,8:177-93.
[17] SU JC,MAR AC,WU SH,et al. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis[J]. Sci Rep,2016,6:28888.
[18] BRUFSKY A,VALERO V,TIANGCO B,et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer:subgroup analysis of the RIBBON-2 trial[J].Breast Cancer Res Treat,2012,133(3):1067-75.
[19] MASSIHNIA D,PEREZ A,BAZAN V,et al. A headlight on liquid biopsies:a challenging tool for breast cancer management[J]. Tumour Biol,2016,37(4):4263-73.
[20] WANG T,SEAH S,LOH X,et al. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway[J]. Oncotarget,2016,7(3):2532-44.